DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Not Applicable

Terminated

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Drug: deferoxamine

First Posted Date: 2008-04-15

Last Posted Date: 2013-04-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00658411

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Pilot Weight Control Intervention at HPHC

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: Counseling Sessions
Behavioral: Specialized Website
Behavioral: Telephone Counseling Calls

First Posted Date: 2008-03-26

Last Posted Date: 2008-03-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT00644202

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Department of Ambulatory Care and Prevention, Boston, Massachusetts, United States

A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors

Phase 1

Terminated

Conditions: Tumors of the Central Nervous System

Interventions: Drug: 18F-FLT
Radiation: PET Imaging

First Posted Date: 2008-03-12

Last Posted Date: 2021-10-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00633958

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: RAD001
Drug: Bicalutamide

First Posted Date: 2008-03-07

Last Posted Date: 2017-12-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT00630344

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Phase 2

Terminated

Conditions: Rectal Cancer

Interventions: Drug: Cetuximab
Drug: 5-Fluorouracil
Radiation: Radiation

First Posted Date: 2008-02-11

Last Posted Date: 2019-01-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 13

Registration Number: NCT00611858

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Vanderbilt Medical Center, Nashville, Tennessee, United States

and more 1 locations

Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Procedure: chest computed tomography scan

First Posted Date: 2008-01-25

Last Posted Date: 2020-01-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 39

Registration Number: NCT00601146

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Web Site and Print Materials Intervention for Smoking Intervention for Childhood and Young Adult Cancer Survivors

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: Web Intervention
Behavioral: print materials

First Posted Date: 2008-01-08

Last Posted Date: 2014-12-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 374

Registration Number: NCT00588107

Locations: 🇺🇸
DFCI, Boston, Massachusetts, United States

Vitamin D for Chemoprevention

Phase 1

Completed

Conditions: Hypertension
Prostate Cancer
Gastrointestinal Cancers

Interventions: Drug: Vitamin D
Dietary Supplement: Placebo

First Posted Date: 2008-01-03

Last Posted Date: 2015-04-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 328

Registration Number: NCT00585637

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2007-12-21

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT00578149

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Phase 2

Completed

Conditions: Mucosal Lentiginous Melanoma
Acral Lentiginous Malignant Melanoma

Interventions: Drug: Sunitinib

First Posted Date: 2007-12-20

Last Posted Date: 2016-12-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 52

Registration Number: NCT00577382

Locations: 🇺🇸
Washington University in St. Louis, St. Louis, Missouri, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy